	2012 Dec 31	C 2013 Dec 31	2014 Dec 31	2015 Dec 31	R 2016 Dec 31	C 2017 Dec 31	2018 Dec 31	2020 Jun 30	2021 Jun 30	2022 Jun 30	2023 Jun 30	2024 Jun 30	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	18M AR	12M AR	12M AR	12M AR	12M AR	9M AR	12M PRESS
Total Revenue	687	798	867	940	993	698	849	1,356	1,009	1,114	1,230	1,151	934	1,408
Cost of Operating Revenue	340	438	483	528	501	328	367	583	378	452	475	436	334	389
Gross Profit	347	359	384	412	492	370	482	773	631	662	755	715	600	1,019
Gross Margin	50.5	45.0	44.3	43.9	49.6	53.0	56.7	57.0	62.6	59.4	61.4	62.1	64.3	72.4
Total Operating Expenses	591	731	821	878	893	623	723	1,067	792	867	921	870	630	975
Operating Profit	97	67	46	61	99	75	126	289	217	247	309	281	304	433
Operating Margin	14.1	8.4	5.3	6.5	10.0	10.8	14.9	21.3	21.5	22.2	25.1	24.4	32.5	30.8
Financing Income/(Expense) - Net	19	21	20	20	23	23	23	60	14	9	14	11	7	-1
Profit before Taxes	117	88	67	83	115	99	158	355	233	253	314	273	312	450
Income Taxes	38	32	23	30	36	38	56	101	56	61	85	72	77	123
Profit after Tax	78	56	43	54	79	94	839	254	177	193	229	201	234	327
PAT Margin	11.4	7.0	5.0	5.7	8.0	13.5	98.8	18.7	17.5	17.3	18.7	17.5	25.1	23.2
EPS - Basic - ex Extraordinary Items	47.23	33.66	26.04	32.27	47.66	36.77	61.29	153.07	106.51	115.98	138.24	121.08	141.00	196.94
EPS - Diluted - ex Extraordinary Items	47.23	33.66	26.04	32.27	47.66	36.77	61.29	153.07	106.51	115.98	138.24	121.08	141.00	196.94
EBIT	97	67	46	61	99	75	126	289	217	247	309	281	304	433
EBITDA	106	77	59	85	124	94	151	318	247	274	336	308	320	457
EBITDA Margin	15.4	9.7	6.8	9.0	12.5	13.5	17.8	23.5	24.4	24.6	27.3	26.8	34.3	32.4

Balance Sheet

Abridged

Understanding Balance Sheet

Procter & Gamble Health Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Dec 31	R 2013 Dec 31	2014 Dec 31	R 2015 Dec 31	R 2016 Dec 31	2017 Dec 31	2018 Dec 31	2020 Jun 30	2021 Jun 30	R 2022 Jun 30	2023 Jun 30	2024 Jun 30	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	458	478	499	564	636	752	1,534	956	727	608	796	524	526	556
Long-Term Investments	-	-	-	-	-	-	4	3	3	3	2	2	4	3
Property Plant & Equipment - Net	77	94	137	139	140	123	117	119	140	150	173	132	122	113
Total Non-Current Assets	136	171	210	214	243	239	225	220	259	280	305	270	268	285
Total Assets	594	648	708	778	879	991	1,759	1,176	986	888	1,101	794	794	841
Total Current Liabilities	97	112	135	150	186	225	196	227	239	232	304	219	215	255
Long Term Debt	-	-	-	-	-	-	-	-	3	-	9	7	5	6
Total Non-Current Liabilities	14	13	19	27	29	33	23	42	43	40	46	37	42	62
Total Liabilities	111	125	154	177	215	258	219	269	282	272	350	256	257	317
Total Shareholders' Equity	484	523	554	601	664	733	1,540	906	704	616	751	538	537	525
Total Equity	484	523	554	601	664	733	1,540	906	704	616	751	538	537	525
Total Liabilities & Equity	594	648	708	778	879	991	1,759	1,176	986	888	1,101	794	794	841

Cash Flow

Abridged

Understanding Cash Flow Statement

Procter & Gamble Health Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Dec 31	2013 Dec 31	2014 Dec 31	C 2015 Dec 31	C 2016 Dec 31	2017 Dec 31	2018 Dec 31	2020 Jun 30	2021 Jun 30	2022 Jun 30	2023 Jun 30	2024 Jun 30	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	18M AR	12M AR	12M AR	12M AR	12M AR	9M AR	12M PRESS
Operating CF bef Changes in Working Cap	84	71	73	84	93	121	-58	302	212	227	280	253	250	372
Working Capital - Increase/(Decrease)	-14	-51	-49	16	30	-48	-50	-6	53	-47	-30	-12	-74	-23
Net CF from Operating Activities	70	20	24	100	123	74	-109	296	264	179	250	241	176	348
Capital Expenditures - Net	13	33	40	45	32	10	19	23	51	38	38	22	1	14
Net CF from Investing Activities	-97	-13	-9	-84	-91	-67	1,248	104	-49	-35	-36	-19	2	-9
Dividends Paid - Cash - Total	-	4	14	10	12	18	25	733	382	284	94	415	232	340
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-	-	-	-	-	-	-	-	-5	-5	-5	-3	-2	-4
Net Cash Flow from Financing Activities	-	-5	-17	-12	-15	-22	-30	-883	-387	-289	-98	-418	-235	-344
Free Cash Flow to Equity	56	-13	-16	55	91	63	-128	273	208	137	208	216	173	330
Free Operating CF net dividend	56	-18	-30	44	79	25	-160	-461	-170	-142	114	-196	-65	-7
Free Operating CF	56	-13	-16	54	91	43	-135	273	212	141	208	219	167	333

Business Segment Analysis

FY End:

Mar 25

Procter & Gamble Health Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 8.56 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 934.17 Cr

Assets

Pharmaceuticals (100.0%)₹ 794.20 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 303.81 Cr

Regional Segment Analysis

FY End:

Mar 25

Procter & Gamble Health Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (93.2%)₹ 870.52 CrOut of India (6.8%)₹ 63.65 Cr

Historical Segment Analysis

Track how Procter & Gamble Health Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2011 Dec 31	2012 Dec 31	2013 Dec 31	2014 Dec 31	2015 Dec 31	2016 Dec 31	2017 Dec 31	2020 Jun 30	2021 Jun 30	2022 Jun 30	2023 Jun 30	2024 Jun 30	2025 Mar 31

Pharmaceuticals	10	9	19	48	25	18	39	23	53	38	42	22	9
Chemicals	5	4	8	8	11	20	9	-	-	-	-	-	-
Eliminations	0	0	0	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Procter & Gamble Health Ltd.?

The latest trailing twelve month revenue of Procter & Gamble Health Ltd. is ₹ 1,407.97 Cr, reflecting a 1-year growth of 15.59% and a 3-year CAGR of 4.77%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Procter & Gamble Health Ltd.?

The latest trailing twelve month net profit (PAT) of Procter & Gamble Health Ltd. is ₹ 326.91 Cr, with a 3-year earnings CAGR of 10.72%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Procter & Gamble Health Ltd.?

The trailing twelve month EBITDA of Procter & Gamble Health Ltd. is approximately ₹ 433.07 Cr (based on an operating margin of 30.76%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Procter & Gamble Health Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Procter & Gamble Health Ltd. is 196.94. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Procter & Gamble Health Ltd.?

The debt-to-equity ratio of Procter & Gamble Health Ltd. stands at 0.02. The interest coverage ratio is 787.40x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Procter & Gamble Health Ltd.?

The estimated book value per share of Procter & Gamble Health Ltd. is 333.65 (derived from a P/B ratio of 19.82 and market price of ₹ 6,612.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Procter & Gamble Health Ltd.?

The trailing twelve month operating cash flow of Procter & Gamble Health Ltd. is ₹ 348.35 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Procter & Gamble Health Ltd. report consolidated or standalone financials?

Procter & Gamble Health Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.